BioGlyco supplement products (including BioGlyco Flow, BioGlyco Capsules, and BioGlyco Blood) are not affiliated with CD BioGlyco.
CD BioGlyco does not manufacture, distribute, or provide after-sales support for these consumer products. For any product-related questions, please contact the original seller directly.
This highly advanced multi-functional targeted formulation features c(RGD)fk peptide functionalized liposomes co-loaded with doxorubicin and dihydroartemisinin nanoparticles. The complex structural framework encapsulates pre-formulated dihydroartemisinin core nanoparticles alongside the hydrophilic anthracycline doxorubicin within its aqueous core matrices, while its exterior lipid bilayer shell is surface-modified with specific cyclic arginylglycylaspartic acid-d-phenylalanyl-lysine (c(RGD)fk) targeting peptides linked via covalent polymer-lipid anchors. This precise modification coordinates a dense target-mimetic ligand array with a dual-phase multi-cargo core, altering overall membrane bending elasticity to completely prevent physical particle aggregation and suppress cargo crystallization across variable laboratory media backgrounds.
Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.
As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.
*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.
CD BioGlyco is a leading biotechnology company specializing in glycobiology. We deliver high-quality products and services to support cutting-edge research worldwide.